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Abstract 
An isoforrn of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) isolated and purified from rabbit brain cytosol has 
previously been demonstrated to catalyze membrane fusion (Glaser and Gross, Biochemistry 33 (1994) 5805-5812; Glaser 
and Gross, Biochemistry 34 (1995) 12193-12203). Herein, we provide evidence suggesting that this GAPDH isoform can 
reconstitute in vitro protein-catalyzed fusion between aturally occurring subcellular membrane fractions involved in insulin 
exocytosis. Utilizing purified rat pancreatic [3-cell plasma membranes and secretory granules, we show that a brain cytosolic 
factor catalyzed the rapid and efficient fusion of these two purified membrane fractions which could be inhibited by a 
monoclonal antibody directed against he brain isoform of GAPDH. Moreover, the brain cytosolic factor also catalyzed the 
fusion of reconstituted vesicles prepared from lipid extracts of islet plasma membranes and secretory granules. Although the 
brain cytosolic factor rapidly catalyzed membrane fusion between islet plasma membranes and secretory granules, it did not 
catalyze fusion between one secretory granule population with another. To identify the potential importance of brain 
cytosolic factor catalyzed membrane fusion in islet cells, we examined extracts of hamster insulinoma tumor cells (HIT cells) 
for fusion-catalyzing activity. A protein constituent was present in HIT cell cytosol which was immunologically similar to the 
rabbit brain GAPDH isoform. Although native HIT cell cytosol did not catalyze membrane fusion, removal of an 
endogenous protein inhibitor unmasked the presence of the protein which catalyzed membrane fusion activity and such 
fusion was ablated by a monoclonal antibody directed against he brain isoform of GAPDH. Collectively, these results 
suggest he possibility that an isoform of brain GAPDH, also evident in HIT cells, can catalyze fusion between the two 
naturally occurring subcellular membrane compartments involved in insulin secretion and suggest a novel paradigm 
potentially coupling glycolytic flux with insulin release. © 1998 Elsevier Science B.V. All rights reserved. 
Abbreviations: FB, fractionation buffer (50 mM MES, 250 mM sucrose, pH 7.2); FCGI, fusion-catalyzing GAPDH isoform; 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HIT, hamster insulinoma tumor; PB, preparation buffer (10 mM MES, 1 mM 
EGTA, pH 6.0); POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; PS, phosphatidylserines; R18, octadecyl rhodamine B-chlor- 
ide; SG, secretory granules; SUV, small unilameUar vesicles 
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1. Introduction 
Insulin is stored in secretory vesicles closely juxta- 
posed to the pancreatic 13-cell plasma membrane. 
Fuel secretagogues, including o-glucose must be me- 
tabolized by pancreatic I]-cells to facilitate the release 
of insulin which is mediated by the fusion of secre- 
tory granules with pancreatic [3-cell plasma mem- 
branes [1-3]. However, the chemical mechanisms 
coupling secretagogue metabolism with l-cell secre- 
tory granule-plasma membrane fusion are not 
known. Moreover, the fusion of pancreatic 13-cell se- 
cretory granules with plasma membranes has never 
been reconstituted in vitro. Recently, we have iden- 
tified the ability of one isoform of an enzyme playing 
a prominent regulatory role in glucose metabolism, 
glyceraldehyde-3-phosphate dehydrogenase from 
brain, to catalyze the fusion of phospholipid vesicles 
comprised of plasmalogen molecular species in vitro 
[4]. Membrane fusion catalyzed by this isoform pos- 
sessed an obligatory dependence on plasmalogens for 
catalytic activity and required the presence of phys- 
iologic amounts of cholesterol and phosphatidylser- 
ine [4]. Plasmalogen molecular species contain a vinyl 
ether linkage at the sn-1 position of the glycerol 
backbone and typically contain polyunsaturated 
fatty acids at the sn-2 position [5,6] resulting in a 
decrease of the cross sectional area at the hydropho- 
bic-hydrophilic nterface and an increased steric bulk 
in the hydrophobic portion of the molecule [7,8]. 
In neurons, both synaptic vesicles and presyn- 
aptic membranes are enriched in plasmenyletha- 
nolamine containing polyunsaturated sn-2 content 
species [9-12] and this is also the case with I]-cell 
plasma membrane and secretory granule mem- 
brane [13,14]. 
The fusion of membrane bilayers is facilitated by 
the transient formation of an intermediate structure 
similar to an inverted micelle where the phospholipid 
head groups are oriented towards the interior of the 
structure, and the aliphatic side chains are directed 
outward (i.e. an inverted hexagonal phase II (H,)) 
[15-20]. The importance of this structure in mem- 
brane fusion is supported by the demonstration of
accelerated rates of membrane fusion in bilayers con- 
taining constituents which promote formation of the 
HI1 phase [17,20-22]. Phospholipids predisposed to 
adopt the H~I configuration are those in which the 
steric bulk of the hydrophobic region greatly exceeds 
that of the polar head group [18,23]. 
Although prior observations demonstrated that a 
brain cytosolic GAPDH isoform catalyzes fusion of 
model plasmenylethanolamine-containing ves cles, it 
is not yet known whether this protein can catalyze 
fusion between naturally occurring biologic mem- 
branes which actually participate in exocytosis in 
vivo. It is also not known whether the fusion-cata- 
lyzing GAPDH isoform (FCGI) is expressed only in 
brain or whether it is also present in other secretory 
cells. Identification of proteins which participate in 
fusion between pancreatic [3-cell plasma membranes 
and secretory granules could have implications for 
the regulation of insulin secretion and perhaps for 
the understanding of insulin secretory defects in 
type II diabetes mellitus. Both islets and neurons 
express a family of proteins involved in the interac- 
tions between secretory granules and plasma mem- 
branes, including syntaxin, synaptobrevin, and 
SNAP-25 [24]. This suggests that there are common 
biochemical features between neurotransmitter re- 
lease and insulin secretion. Despite the importance 
of the identification of proteins which facilitate insu- 
lin exocytosis, no candidate protein has yet been 
demonstrated to catalyze the fusion of secretory 
granules and plasma membranes i olated from pan- 
creatic islets despite early suggestions that such a 
factor might exist. In view of the biochemical simi- 
larities between eurotransmitter r lease and insulin 
secretion, and of the similar phospholipid composi- 
tion of 13-cell and neuronal membranes, we have ex- 
amined the possibility that the fusion-catalyzing 
GAPDH isoform isolated from brain might also cat- 
alyze fusion between insulin secretory granules and 
islet plasma membranes. Herein we demonstrate he 
ability of a protein present in brain to effectively 
catalyze the fusion of pancreatic islet plasma mem- 
branes with secretory granules in vitro and that this 
activity is ablated by monoclonal antibody directed 
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against GAPDH. Moreover, we demonstrate the 
presence of a similar protein constituent in HIT cells 
which is chromatographically and immunologically 
similar to the GAPDH isoform and thus represents 
a candidate protein for catalyzing the exocytosis of 
insulin from [~-cells in vivo. 
2. Materials and methods 
2.1. Materials 
Octadecyl rhodamine B-chloride (R18) was pur- 
chased from Molecular Probes (Eugene, OR) and 
purified on an Altex Ultrasphere-CN column as de- 
scribed previously [4]. Bovine brain phosphatidylser- 
ine (PS) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phos- 
phocholine (POPC) were purchased from Avanti 
Polar Lipids (Birmingham, AL) and purified on an 
Altex Ultrasphere-Si column as described previously 
[4]. Plasmenylethanolamine from bovine heart etha- 
nolamine glycerophospholipids was purified by re- 
verse phase HPLC [23]. All phospholipids were 
quantified by capillary gas chromatography after 
acid methanolysis by comparison with methyl arach- 
idate internal standard as described previously [25]. 
Most other chemicals were obtained from Sigma (St. 
Louis, MO). 
2.2. Preparation of rat islet secretory granules and 
plasma membranes 
Rat islet plasma membranes, ecretory granules 
and mitochondria were prepared by sucrose density 
gradient centrifugation [14]. Briefly, rat islets (ca. 
9000) were transferred to a tissue grinder, rinsed 
twice with fractionation buffer (FB, 50 mM MES, 
250 mM sucrose, pH 7.2), resuspended in 0.80 ml 
of FB, and homogenized with 14 strokes of the pestle 
at 1170 rpm (Polyscience RX R10 at setting 3). The 
homogenate was centrifuged at 600 X gmax for 5 min 
and the resultant supernatant was centrifuged at 
20000Xgmax for 20 min. The resulting pellet was 
resuspended in 0.20 ml of preparation buffer (PB, 
10 mM MES with 1 mM EGTA, pH 6.0) and was 
rehomogenized (14 strokes, 1170 rpm), layered atop 
a discontinuous sucrose gradient comprised of 1 ml 
each of sucrose at relative densities of 1.14, 1.16, 
1.18, and 1.20 in a Beckman cellulose nitrate centri- 
fuge tube (Ultraclear 13 x 51 mm), and centrifuged at 
150000Xgmax for 90 min. The bands enriched in 
plasma membranes (top two interfaces) and secretory 
granules (present at the bottom two interfaces) were 
harvested separately [26]. Next, each fraction was 
resuspended in 4.0 ml of PB and centrifuged at 
150000 ×gmax for 60 min (to remove sucrose) and 
the resulting pellets were resuspended in 0.50 ml of 
10 mM MES buffer (pH 6.0). Both acid-extractable 
insulin (marker for secretory granules) and 5'-nucle- 
otidase activity (marker for plasma membranes) were 
measured as previously described [14]. 
2.3. Preparation of insulin secretory granules by 
Percoll density gradient fractionation 
To obtain a homogeneous population of secretory 
granules free of mitochondria, the following proce- 
dure was employed. All operations were performed 
at 4°C. Islets (ca. 9000) were homogenized as de- 
scribed above in secretory granule (SG) buffer (0.8 
ml of 260 mM sucrose, pH 6.5, with 10 mM MOPS 
(4-morpholinepropanesulfonic acid)) [27]. The homo- 
genate (H) was transferred to a 10 ml glass vial and 
diluted with 7.2 ml of SG buffer. One ml of this 
suspension was then placed in each of eight Eppen- 
dorf 1.5 ml polypropylene tubes and centrifuged at 
900×gmax for 5 min to yield a pellet (P1) and a 
supernatant (S1). Each 1 ml of S1 was then centri- 
fuged (13000Xgmax, 10 min) separately in a Eppen- 
doff 1.5 ml polypropylene tube to yield a pellet (P2) 
and a supernatant (S2). P2 was then resuspended in 
0.6 ml of SG buffer and 0.1 ml of the suspension was 
layered atop each of 6 Percoll density gradients. 
Each consisted of a layer (50 gl) of 100% Percoll 
and a layer (250 ~tl) of 35% Percoll in a 400 gl Ep- 
pendorf polypropylene tube. The Percoll had been 
dialyzed for 24 h against SG buffer before prepara- 
tion of the gradients. After centrifugation at 
13000Xgma x for 10 min, the lower 150 gl of the 
gradient (which contained the secretory granule frac- 
tion [27]) was then removed with a 500 gl Hamilton 
syringe. The Percoll content of the SG fraction was 
98 X. Han et al./Biochimica et Biophysica Acta 1414 (1998) 95-107 
then reduced by dilution with 1 ml of SG buffer and 
was subsequently centrifuged at 13 000 Xgma x for 10 
min. An aliquot of fractions H, S1, P1, $2, P2, SG, 
were removed for measurement of protein, and the 
remainder was processed for measurement of acid- 
extractable insulin [14]. 
2.4. Preparation of the crude GAPDH isoform 
membrane fusion activity from rabbit brain 
cytosol and HIT insulinoma cell cytosol 
Crude fusion-catalyzing GAPDH isoform (FCGI) 
from rabbit brain cytosol was prepared as described 
previously [4]. Briefly, rabbit brains harvested from 
New Zealand white rabbits were homogenized with a 
Brinkman PT 10/35 Polytron apparatus. Crude cyto- 
sol was prepared by sequential centrifugation of the 
homogenate at 10 000 X gmax for 20 min and the re- 
sultant supernatant was further centrifuged at 
100 000 X gmax for 60 min. The supernatant (cytosol) 
was twice dialyzed against 500 vols. of buffer A (50 
mM Tris-HC1, 0.1 mM EGTA, 0.1 mM EDTA, and 
1 mM DTT, pH 7.0 at 4°C) for 6 h. The dialyzed 
cytosol was applied to a DE-52 (2.6 cmx20 cm) 
column previously equilibrated with buffer A. After 
loading the cytosol, the column was washed with 
buffer A and the flow-through fractions were as- 
sessed for, and contained, membrane fusion activity 
as previously described [4]. To determine whether 13- 
cells express an analogous fusion-catalyzing protein, 
dialyzed cytosol from HIT insulinoma cells (ca. 
3 x 109) was prepared in a manner similar to that 
described above. Briefly, HIT insulinoma cells were 
resuspended in 5 ml of homogenization buffer (250 
mM sucrose, 50 mM Tris-HC1, 10 mM EGTA, 2 mM 
EDTA, and 1 mM DTT, pH 7.4 at 25°C) and cells 
were homogenized by brief sonication (10 × 1 s pulse) 
at 0°C. Crude cytosol was obtained by sequential 
centrifugations of the homogenate first at 
10 000 × gmax for 20 min and subsequent centrifuga- 
tion of the supernatant a 100000Xgmax for 60 rain. 
The resultant cytosolic supernatant cytosol was twice 
dialyzed against 500 vols. of buffer A for 6 h. The 
dialyzed HIT cell cytosol was applied to a DE-52 
(1 cm× 10 cm) column previously equilibrated with 
buffer A. The void fractions were collected and as- 
sayed for membrane fusion-catalyzing activity as de- 
scribed below. 
2.5. Preparation and purification of monoclonal 
antibodies 
Hybridomas were prepared from mouse spleen 
after injection of purified membrane fusion protein 
[4] and were used to generate ascites fluid by estab- 
lished methods [28]. The resultant IgG was purified 
from ascites fluid by a protein A-agarose affinity 
chromatography kit (Pierce, Rockford, IL). Briefly, 
diluted ascites fluid (diluted 1:1 (v/v) with supplied 
binding buffer) was centrifuged at 2000 X gmax for 5 
rain and the supernatant was loaded onto a protein 
A-agarose column previously equilibrated with bind- 
ing buffer. After being extensively washed with bind- 
ing buffer, IgG was eluted with the supplied high salt 
eluent buffer. The salt eluate was subsequently 
loaded onto an Excellulose GF-5 desalting column 
previously equilibrated with PBS buffer, and the 
monoclonal antibody was eluted with PBS buffer. 
2.6. Labeling of pancreatic islet secretory granules 
with R18 
Labeling of pancreatic slet secretory granules with 
R18 was performed as described previously [29] with 
minor modification. Briefly, aliquots of a solution of 
R18 (0.5 mg/ml) in CHC13 were placed in glass test 
tubes, concentrated to dryness under nitrogen and 
then exhaustively evacuated at high vacuum for at 
least 30 min. A suspension of islet secretory granules 
was then added to the test tube and was incubated 
for 5 min at 37°C with gentle shaking. The resultant 
suspension was then transferred to a new test tube 
and centrifuged at 900Xgmax for 10 min. The resul- 
tant pellet (which contained R18-1abeled secretory 
granules) was resuspended in the fusion assay buffer 
(280 mM sucrose, 5 mM MES, pH 6.0) at a concen- 
tration of 0.2 mg protein/ml. 
2. 7. Membrane fusion assays 
Fusion of rat islet secretory granules with islet 
plasma membranes (or secretory granules) was meas- 
ured by R18 fluorescence-dequenching as described 
in detail previously [30]. This R18 fluorescence-de- 
quenching technique has been commonly used for 
fusion assays in biological membrane systems 
[29,31-36]. Briefly, R18-1abeled secretory granules 
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(typically, 10 ~tg protein) and unlabeled plasma mem- 
branes (typically, 4 p.g protein) were added to a fluo- 
rescence cuvette containing 1ml of fusion assay buf- 
fer and stirred at 37°C. Fluorescence was measured 
continuously utilizing an SLM-Aminco 4800C spec- 
trofluorometer operating at an excitation wavelength 
of 560 nm and an emission wavelength of 590 nm. 
After a stable baseline fluorescence was recorded (ca. 
100 s), crude rabbit brain cytosolic FCGI (typically 
100 ~tl) was added in the absence or presence of other 
reagents as indicated. The mixture was continuously 
stirred and fluorescence was monitored for an addi- 
tional 500 s. Control assays utilizing combinations of 
labeled and unlabeled secretory granules or of la- 
beled and unlabeled plasma membranes were also 
performed as indicated. Fluorescence-dequenching 
was expressed as a percentage of maximal fluores- 
cence intensity, which was defined as that observed 
after addition of Triton X-100 (0.2%, v/v) to the 
assay cuvette. 
To determine whether the void fractions from DE- 
52 chromatographic analysis of HIT cell cytosol con- 
tained fusion catalyzing activity, fluorescence-de- 
quenching measurements were performed with model 
phospholipid vesicles [4]. Small unilamellar vesicles 
(SUV) were prepared which contained POPC (27 
mol%), plasmenylethanolamine (27 mol%), PS (6 
mol%), and cholesterol (40 mol%) at a final lipid 
concentration of 200 ~tM in fusion assay buffer 
(100 mM NaC1, 5 mM MES, 0.1 mM EGTA, pH 
6.0). Preparation of the vesicles involved sonication 
utilizing a 40% duty cycle at a power level of 1.5 with 
a Vibra Cell sonicator equipped with a small tip. 
Labeled SUV containing R18 (2 mol%o) were also 
prepared. Equimolar amounts of labeled and unla- 
beled SUV were loaded into one chamber of an SLM 
Aminco 4800C spectrofluorometer quipped with 
SLM stopped-flow apparatus. The other chamber 
was loaded with either dilution buffer alone 
(100 mM NaC1, 50 mM MES, and 0.1 mM EGTA, 
pH 6.0) or with protein-containing fractions diluted 
with dilution buffer in the absence or presence of 
other reagents as indicated. The contents of the 
two chambers were rapidly mixed in a 1 : 1 (v/v) ratio. 
Fusion was monitored by the temporal dependence 
of R18 fluorescence-dequenching observed at an 
emission wavelength of 590 nm with an excitation 
wavelength of 560 nm. The 0% fusion level was de- 
termined by monitoring fluorescence when the 
vesicles were mixed with sample dilution buffer 
only. The 100% fusion level was determined by pre- 
paring vesicles composed of the mixture which would 
result if all vesicles fused (e.g. 27% PC, 27% PE, 6% 
PS, 40% cholesterol, and 1% R18) and quantifying 
the resultant R18 fluorescence. The fluorescence trac- 
ings were normalized to the 0% and 100% fusion 
levels. Fusion of rat islet secretory granules with islet 
plasma membranes induced by the void fractions 
from DE-52 chromatography of HIT cell cytosol 
was determined by fluorescence dequenching as de- 
scribed above. 
Fusion of reconstituted lipid extracts of rat islet 
secretory granules and plasma membranes was also 
examined by fast stopped-flow kinetic analysis. 
Briefly, total membrane lipids of rat islet secretory 
granules and plasma membranes were extracted by 
the Bligh and Dyer method [37]. Small unilamellar 
vesicles comprised of membrane lipid extracts were 
prepared by sonication in fusion assay buffer (100 
mM NaC1, 5 mM MES, and 0.1 mM EGTA, pH 
6.0) to achieve a final total lipid concentration of 
,'~ 200 ~tM. R18-1abeled (2 moP/o) small unilamellar 
vesicles of extracted lipids were prepared similarly. In 
some experiments, Bligh and Dyer extracts were 
treated with HC1 fumes for 30 min to destroy plas- 
malogens as described previously [19]. Fast stopped- 
flow kinetic analysis of FCGI-induced fusion of these 
SUV was performed as described above. 
2.8. Miscellaneous procedures 
Protein content was determined with a Bio-Rad 
protein assay using bovine serum albumin as stand- 
ard. Trypsin-digestion f proteins or membranes was 
performed by incubation with 0.5% (w/w) of TPCK 
trypsin (Pierce) at 37°C for ~, 1 h and terminated by 
addition of 0.1% (w/w) trypsin inhibitor. 
3. Results 
3.1. A rabbit brain cytosolic factor induces fusion of 
islet secretory granules with islet plasma 
membranes 
When R18-1abeled islet secretory granules were 
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mixed with unlabeled islet plasma membranes in the 
absence of any DE-52 eluent, no significant fluores- 
cence-dequenching (other than a normal background 
drift) was observed (tracing A, Fig. 1), indicating 
that these two membrane populations do not sponta- 
neously fuse at measurable rates. Addition of DE-52 
chromatographic eluents of rabbit brain cytosol in- 
duced the rapid fusion of the islet secretory granules 
with plasma membranes in a concentration-depend- 
ent manner (Fig. 1, upper three tracings). 
To determine whether both membrane populations 
are required in the fusion event, two additional ex- 
periments were performed. First, R18-1abeled islet 
secretory granules were mixed with unlabeled islet 
secretory granules and fluorescence-dequenching 
was monitored after addition of brain cytosolic fu- 
sion-catalyzing factor. After an initial decrease in 
fluorescence (tracing B in Fig. 2) minimal fluores- 
cence-dequenching, similar to the control tracing A 
in Fig. 1 and probably reflecting a background rift 
or dilution effect, was observed. The absence of sig- 
nificant dequenching above background therefore in- 
dicates that secretory granules do not spontaneously 
fuse with each other. Fusion did occur when brain 
cytosolic factor was added to a mixture of unlabeled 
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Fig. 1. Fusion of islet secretory granules with plasma mem- 
branes is induced by a rabbit brain cytosolic factor. R18-1abeled 
islet secretory granules (10 lag protein) were mixed with islet 
plasma membranes (4 lag protein), and fluorescence-dequenching 
was monitored after addition of varied amounts of fusion-cata- 
lyzing protein (A to D, 0, 7.5, 15, 30 lag of protein, respec- 
tively) obtained from DE-52 chromatography of dialyzed rabbit 
brain cytosol. Fluorescence was measured continuously with an 
SLM-Aminco 4800C spectrofluorometer operated at an excita- 
tion wavelength of 560 nm and an emission wavelength of 590 
nm. Fluorescence-dequenching is expressed as a percentage of 
the fluorescence intensity after addition of Triton X-100 (0.2%, 
v/v) to the assay cuvette at the end of the experiment. 
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Fig. 2. The rabbit brain cytosolic factor catalyzes fusion of 
R18-1abeled islet secretory granules with unlabeled islet plasma 
membranes but not with unlabeled islet secretory granules. 
R18-1abeled islet secretory granules (10 lag protein) were mixed 
with unlabeled islet plasma membranes (4 /,tg protein, A) or 
with unlabeled secretory granules (10 lag protein, B), and fluo- 
rescence was recorded before and after addition (at arrow) of 
an aliquot (30 lag protein) of the void volume fractions from 
DE-52 chromatography of dialyzed rabbit brain cytosol. Fluo- 
rescence was quantitated asdescribed in the legend of Fig. 1. 
plasma membranes and R18-1abeled secretory gran- 
ules (tracing A in Fig. 2). This indicates that plasma 
membranes are required for the fusion event. In the 
second experiment, he effects of varying the concen- 
trations of secretory granules on membrane fusion 
were examined. As illustrated in Fig. 3, fusion be- 
tween islet secretory granules and plasma membranes 
was dependent on the concentration of plasma mem- 
brane. Similarly, in experiments where the concentra- 
tion of plasma membrane was fixed, the amplitude of 
fusion was observed to increase as the concentration 
of secretory granules was increased (data not shown). 
This demonstrates that both islet membrane com- 
partments are required for fusion induced by the 
brain cytosolic factor. 
3.2. The fusion-catalyzing factor from brain cytosol is 
a protein 
To determine whether the activity from brain cy- 
tosol which catalyzes the fusion between islet plasma 
membranes and secretory granules was mediated by 
a protein, the DE-52 void fractions (which contained 
the activity) were pretreated with trypsin as described 
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Fig. 3. The rate of membrane fusion induced by brain cytosolic 
fusion-catalyzing factor depends on the concentration of both 
islet plasma membranes and secretory granules. A fixed amount 
of R18-1abeled islet secretory granules (I0 ~g protein) was 
mixed with varied amounts of unlabeled islet plasma mem- 
branes. The amounts of plasma membranes employed contained 
2, 4, 8, 12 or 16 lag protein in tracings A, B, C, D, or E, re- 
spectively. Fluorescence was monitored before and after addi- 
tion (at arrow) of an aliquot of fusion-catalyzing protein (30 
lag) contained in the void volume fractions from DE-52 chro- 
matography of dialyzed rabbit brain cytosol. Membrane fusion 
was quantified as described in the legend of Fig. 1. 
in Section 2. Fluorescence-dequenching was then 
monitored after adding the trypsin-treated DE-52 
void fractions to a mixture of R18-1abeled islet secre- 
tory granules and unlabeled islet plasma membranes 
(Fig. 4, top panel). Fusion-catalyzing activity of the 
brain cytosolic factor was completely ablated by 
trypsin-treatment (tracing B) although non-trypsin- 
treated cytosolic factor did catalyze fusion (tracing 
A). This indicates that a protein constituent in the 
DE-52 void fraction was responsible for catalyzing 
fusion between islet plasma membranes and secretory 
granules. 
Because intrinsic membrane proteins are required 
for exocytosis [38,39], interaction of the fusion pro- 
tein with islet plasma membranes or secretory gran- 
ules may require proteins exposed on the surface of 
these membranes. Therefore, both labeled islet secre- 
tory granules and unlabeled islet plasma membranes 
were treated with trypsin prior to mixing, and fluo- 
rescence-dequenching induced by the partially puri- 
fied fusion protein was monitored (Fig. 4, bottom 
panel). The rate of fusion with trypsin-treated islet 
secretory granules and trypsin-treated plasma mem- 
branes was nearly identical to that observed with 
islet secretory granules and plasma membranes 
that had not been treated with trypsin (tracings A 
and B). 
30- -  
20- -  
¢~ 10- -  
E 0 - -  
Z 
a 
8 
.= 
E 
30-  
~ A 
~ c  
I I I I I 
100 200 300 400 500 600 
Time (see) 
20-  
10-  
0 -  
. y  B 
= A 
0 100 200 300 4 5 0 600 
Time (sec) 
Fig. 4. Ablation of fusion of islet secretory granules and plasma 
membranes following trypsinization of brain cytosolic factor 
but not of plasma membrane. Top panel: R18-1abeled islet se- 
cretory granules (10 lag protein) and unlabeled islet plasma 
membranes (4 lag protein) were mixed as in Fig. 1. Fluorescence 
was monitored before and after addition (at arrow) of an ali- 
quot (30 lag protein) of void volume fractions from DE-52 
chromatography of dialyzed rabbit brain cytosol (A), of tryp- 
sin-treated DE-52 eluate (B), or of buffer alone (C). Fusion was 
quantified as described in the legend of Fig. 1. Bottom panel: 
preparations of islet secretory granules and of plasma mem- 
branes were each divided into two aliquots. One aliquot of 
each membrane preparation was incubated with trypsin (0.5% 
(w/w), 1 h, 37°C) and the other aliquot was incubated (1 h, 
37°C) without trypsin. The membranes were then collected by 
centrifugation and resuspended in trypsin-free buffer. This proc- 
ess was repeated to remove any residual trypsin. Next, secretory 
granules were then labeled with R18 as described in Section 2. 
Trypsin-treated labeled secretory granules were then mixed with 
unlabeled, trypsin-treated plasma membranes (tracing A). Con- 
trol experiments involving mixing of non-trypsin-treated labeled 
secretory granules with non-trypsin-treated, unlabeled plasma 
membranes are illustrated in tracing B. Fluorescence was moni- 
tored before and after addition (at arrow) of an aliquot of fu- 
sion-catalyzing protein (30 lag) contained in the void volume 
fractions from DE-52 chromatography of dialyzed rabbit brain 
cytosol. Membrane fusion was quantified as described in the 
legend of Fig. 1. 
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Fig. 5. Fusion of islet secretory granules and plasma mem- 
branes catalyzed by a brain cytosolic factor is ablated by anti- 
body directed against glyceraldehyde-3-phosphate dehydrogen- 
ase. R18-1abeled islet secretory granules (10 pg protein) were 
mixed with unlabeled islet plasma membranes (4 I.tg protein). 
Fluorescence was then monitored before and after addition (at 
arrow) of an aliquot of fusion-catalyzing protein (30 ~g) con- 
tained in the void volume fractions from DE-52 chromatogra- 
phy of dialyzed rabbit brain cytosol that bad been premixed 
with buffer control (tracing A), Ab 155.B5.4 (10 pg) (tracing B) 
or with anti-GAPDH antibody Ab 155.D2.2 (1 pg) (tracing C) 
as described in Section 2. Membrane fusion was quantified as 
described in the legend of Fig. 1. 
3.3. The protein catalyzing fusion between islet 
secretory granules and plasma membranes i
neutralized by an antibody against 
glyceraldehyde-3-phosphate dehydrogenase 
A monoclonal antibody (Ab 155.D2.2) raised 
against GAPDH has been demonstrated to prevent 
fusion of plasmenylethanolamine-containing SUV 
that is otherwise induced by the rabbit brain cyto- 
solic fusion-catalyzing factor [4]. In contrast, a sec- 
ond antibody also directed against GAPDH (Ab 
155.B5.4) recognizes the protein in Western blots, 
but does not influence membrane fusion activity [4]. 
Fusion of islet plasma membranes with secretory 
granules induced by the rabbit brain cytosolic factor 
was prevented by Ab 155.D2.2, but was not attenu- 
ated by antibody Ab 155.B5.4 (Fig. 5). This indicates 
that the protein in rabbit brain cytosol which cata- 
lyzes fusion of islet plasma membranes and secretory 
granules shares epitopes with the isoform of 
GAPDH which facilitates membrane fusion. This is 
consistent with the possibility that the protein medi- 
ating the fusion of islet cell plasma membranes with 
secretory granules is a GAPDH isoform. 
3.4. Fusion between vesicles prepared from lipid 
extracts of islet secretory granules and plasma 
membranes and the influence of acid treatment of 
the lipid extracts 
To determine whether lipid components of islet 
membrane preparations are important in the cata- 
lyzed fusion event, lipids were extracted from islet 
plasma membranes and secretory granules by the 
method of Bligh-Dyer and used to prepare SUV. 
The SUV prepared from the secretory granules ex- 
tracts were labeled with R18 and mixed with unla- 
beled SUV prepared from islet plasma membranes. 
In some cases, the lipid extracts were treated with 
HC1 vapor before preparation of SUV. Exposure to 
acid fumes under the conditions employed estroys 
the vinyl ether linkage present in plasmalogen molec- 
ular species [19]. After mixing the labeled SUV with 
unlabeled SUV, rabbit brain cytosolic fusion factor 
was added and fluorescence-dequenching was moni- 
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Fig. 6. Fusion of vesicles comprised of reconstituted lipid ex- 
tracts of islet secretory granules and plasma membranes i  cata- 
lyzed by the rabbit brain cytosolic factor. Islet secretory gran- 
ules and plasma membrane lipids were extracted by the Bligh- 
Dyer method. These extracted lipids were used to prepare R18- 
labeled SUV and unlabeled SUV by sonication as described in 
Section 2. In some cases, the lipid extracts were treated with 
HC1 fumes to destroy plasmalogen content before preparation 
of SUV. Fusion between various SUV preparations was then 
monitored by fluorescence-dequenching after addition of an ali- 
quot (30 pg) of rabbit brain cytosolic fusion factor as in Fig. 1. 
In tracing A, R18-1abeled SUV prepared from secretory granule 
lipid extracts were mixed with unlabeled SUV prepared from 
plasma membrane lipid extracts. In tracing B, labeled SUV pre- 
pared from secretory granule lipid extracts were mixed with un- 
labeled SUV prepared from HCl-treated plasma membrane lipid 
extracts. In tracing C, labeled SUV prepared from HCl-treated 
secretory granule lipid extracts were mixed with unlabeled SUV 
prepared from HCl-treated plasma membrane lipid extracts. 
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Fig. 7. Brain cytosolic factor-catalyzed fusion of islet plasma 
membranes with islet secretory granules prepared by Percoll 
density gradient analysis. A population of islet secretory gran- 
ules free of mitochondria was prepared by Percoll density gra- 
dient analysis, as described in Section 2. An aliquot (10 gg pro- 
tein) of R18-1abeled secretory granules was mixed with plasma 
membranes (4 gg protein). Fluorescence was then monitored 
before and after addition (at arrow) of an aliquot of fusion-cat- 
alyzing factor (30 gg protein) contained in the void volume 
fractions from DE-52 chromatography of dialyzed rabbit brain 
cytosol (tracing A). Fusion was quantified as described in the 
legend of Fig. 1. In a separate xperiment, both the secretory 
granule and plasma membrane fractions were treated with tryp- 
sin prior to use in the fusion assay (tracing B). 
tored. Although fusion occurred readily between 
SUV prepared from extracts of islet secretory gran- 
ules and SUV prepared from islet plasma mem- 
branes, pretreatment of the plasma membrane and 
secretory granule membrane extracts with HC1 fumes 
ablated membrane fusion (Fig. 6). These observa- 
tions suggest hat an acid-labile phospholipid (i.e. 
plasmalogen) is a required component of the SUV 
in order for protein-catalyzed fusion to occur. How- 
ever, the possibility that plasmalogen breakdown 
fragments (i.e. lysoglycerophospholipid an  fatty al- 
dehyde) inhibit the protein-catalyzed fusion cannot 
be excluded since prior studies demonstrated that 
lysophosphatidylcholine is a potent inhibitor of 
membrane fusion [40]. 
3.5. Effects of Ca :+ on islet membrane fusion 
catalyzed by the brain cytosolic protein 
Fusion of plasmenylethanolamine-containing SUV 
catalyzed by the rabbit brain cytosolic GAPDH iso- 
form does not require Ca 2÷ [4]. Similarly, rates of 
fusion of islet plasma membranes and secretory gran- 
ules catalyzed by the rabbit brain cytosolic proteins 
were nearly identical in the absence and in the pres- 
ence of 5 mM Ca 2÷ (data not shown). 
3.6. Demonstration ffusion between secretory 
granules prepared by Percoll density gradient 
analysis and plasma membranes 
Subcellular fractionation of islets by sucrose den- 
sity gradient analysis yields a relatively pure popula- 
tion of plasma membranes. Secretory granule-con- 
taining fractions from this procedure also contain 
mitochondria [14,26]; islet secretory granules free of 
mitochondria were prepared by Percoll density gra- 
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Fig. 8. Cytosol from HIT insulinoma cells contains a factor 
which catalyzes fusion of plasmenylethanolamine-containing 
small unilamellar vesicles. Small unilamellar vesicles (SUV) con- 
taining plasmenylethanolamine/POPC/PS/cholesterol (27:27:6:40 
mol%) were prepared as described in Section 2. One population 
of this SUV was labeled with R18. Dialyzed HIT cell cytosol 
was prepared and then analyzed by DE-52 anion exchange 
chromatography as described in Section 2. Labeled and unla- 
beled SUV were then mixed and fluorescence dequenching was 
monitored as in Fig. 1 after addition of crude dialyzed HIT cell 
cytosol (tracing D) or of void-volume fractions obtained from 
DE-52 anion exchange analysis of dialyzed HIT cell cytosol 
(tracing A). In tracings B, C, and E the DE-52 void volume 
fractions were treated with Ab 155.B.5.4, Ab 155.D2.2 or with 
trypsin (0.5%, 1 h, 37°C), respectively, before addition to the 
SUV mixtures. Insert: DE-52 void fraction prepared from HIT 
cell cytosol containing fusion activity was analyzed by SDS- 
PAGE (10%) and the resolved proteins were transferred onto 
Immobilon-P VDF membranes. The electroblot was blocked 
with TBS (1 mM Tris-HC1, 0.14 M NaC1, pH 7.4) buffer con- 
taining 5% powdered milk protein and 0.05% Tween 20, and se- 
quentially incubated with Ab 155.D2.2, then with peroxidase- 
conjugated goat anti-mouse IgG antibody, followed by en- 
hanced chemiluminescence reagent (for 1 min). The proteins 
were subsequently visualized by exposure of the blot to Hyper- 
film ECL for 10 s. 
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Fig. 9. Cytosol from HIT insulinoma cells contains a factor 
which catalyzes fusion of islet secretory granules and plasma 
membranes. R18-1abeled islet secretory granules (10 gg protein) 
were mixed with unlabeled islet plasma membranes (4 gg pro- 
tein). Fluorescence was monitored before and after addition (in- 
dicated by arrow) of crude dialyzed HIT cell cytosol (tracing B) 
or after addition of the void volume obtained from DE-52 
anion exchange chromatography of dialyzed HIT cell cytosol 
(tracing A). Membrane fusion was quantified as described in
the legend of Fig. 1. 
dient analysis [14,27]. When R18-1abeled secretory 
granules prepared by this method were mixed with 
plasma membranes, fluorescence-dequenching was
observed upon addition of brain cytosolic fusion-cat- 
alyzing factor (Fig. 7), indicating the fusion of highly 
purified secretory granules with plasma membranes. 
The ability of the brain cytosolic fusion-catalyzing 
factor to promote fusion was not affected by prior 
treatment of secretory granules and plasma mem- 
branes with trypsin (Fig. 7), suggesting that the fu- 
sion event does not require membrane proteins that 
are digestible by trypsin under the conditions em- 
ployed. 
3. 7. Membrane fusion-catalyzing activity f rom HIT  
insulinoma cells 
These observations suggested the possibility that a 
GAPDH isoform in ~-cells might catalyze fusion be- 
tween secretory granule and [3-cell plasma mem- 
branes. Crude, dialyzed HIT cell cytosol was pre- 
pared, but did not promote fusion of 
plasmenylethanolamine-containing SUV when uti- 
lized directly (Fig. 8). However, when the cytosol 
was subjected to DE-52 anion exchange chromato- 
graphic analysis, fusion-catalyzing activity was 
present in the void volume (Fig. 8). These results 
demonstrate that the fusion catalyzing activity in 
HIT cell cytosol, similar to that in brain cytosol, is 
latent and is observed only after removal of an en- 
dogenous inhibitor which binds to the anion ex- 
change matrix [4]. Like the analogous activity from 
brain cytosol, HIT cell fusion catalyzing activity was 
trypsin-sensitive, and was neutralized by a monoclo- 
nal GAPDH antibody (Ab 155.D2.2) (Fig. 8). West- 
ern analyses (Fig. 8 insert) revealed the recognition 
by this antibody of a single protein band in the re- 
gion corresponding to the molecular mass of 
GAPDH (38 kDa). Collectively, these results indicate 
that the HIT cell fusion-catalyzing protein, like that 
from brain cytosol, shares epitopes with GAPDH 
and may represent a GAPDH isoform. Further ex- 
periments were performed to examine whether this 
protein catalyzing membrane fusion from HIT insu- 
linoma cells can also induce the fusion of rat islet 
secretory granules with islet plasma membranes. As 
before, crude dialyzed HIT cell cytosol did not in- 
duce fusion when used directly (tracing B in Fig. 9). 
However, when the void fractions from DE-52 chro- 
matographic analysis of HIT cell cytosol were rap- 
idly mixed with plasma membranes and secretory 
granules membrane fusion was manifest (tracing A 
in Fig. 9). 
4. Discussion 
The results of the present study demonstrate hat 
pancreatic islet cell plasma membranes and secretory 
granules can be induced to fuse by a cytosolic pro- 
tein constituent present in both rabbit brain and 
hamster insulinoma cells which is immunologically 
related to an isoform of GAPDH. This protein-medi- 
ated fusion of pancreatic slet cells plasma membrane 
and secretory granules is dependent upon the lipid 
components of each membrane since fusion can be 
reconstituted with vesicles prepared from lipid ex- 
tracts of each membrane. The identification that an 
acid-labile constituent is necessary for GAPDH iso- 
form catalyzed membrane fusion is consistent with 
the previous demonstration that the rabbit brain cy- 
tosolic factor only catalyzes fusion of membranes 
which contain plasmalogen molecules species [4]. 
The results described here are the first to demon- 
strate the in vitro reconstitution of membrane 
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fusion between the two naturally occurring subcellu- 
lar compartments involved in insulin secretion in 
vivo. 
Pancreatic islet plasma membranes are highly en- 
riched in arachidonic acid-containing plasmenyletha- 
nolamine molecular species [13,14] and this has also 
recently been demonstrated to be the case for insulin 
secretory granule membranes [76]. The importance of 
plasmenylethanolamine in facilitating both spontane- 
ous and protein-catalyzed membrane fusion [4,19] 
likely reflects the propensity of plasmenylethanol- 
amine molecular species to adopt a conformation 
similar to the inverted hexagonal phase. In the case 
of plasmenylethanolamine-containing membrane 
vesicles, spontaneous fusion occurs slowly, but can 
be accelerated over 1000-fold by a brain cytosolic 
protein constituent that is chemically, chromato- 
graphically, and immunologically similar to an iso- 
form of GAPDH [4]. Previous studies have demon- 
strated that apposition of secretory granules with 
plasma membranes in neurons and in other cell types 
is facilitated by a complex set of interactions between 
docking proteins, proteins facilitating the ATP-de- 
pendent conformational reorganization of these pro- 
teins (e.g. NSF) and the proteins involved in catalyz- 
ing the fusion event itself [39,41-43]. In the current 
study, we supplanted the requirement for docking 
proteins by utilization of high concentrations of 
vesicles which interact through diffusion to study 
GAPDH isoform-catalyzed membrane fusion. Under 
these conditions, fusion from productive intervesicu- 
lar encounters can be catalyzed by a cytosolic factor 
from brain and insulinoma cells which is distinct 
from known docking proteins. In the pancreatic [~- 
cell, secretory granule movement along cytoskeletal 
elements towards the plasma membrane occurs [44], 
and it is likely that cytosolic proteins present in the 
13-cell are also involved in regulation of the exocy- 
totic event, by analogy with other systems [38]. It is 
also likely that the cytosolic factor described here 
participates in catalyzing the actual membrane fusion 
event after docking of the membranes has occurred 
[24]. 
Insulin secretion from pancreatic islet 13-cells re- 
quires the fusion of insulin-containing secretory 
granules with the 13-cell plasma membrane. The mo- 
lecular mechanisms underlying this fusion process 
are incompletely understood. Apposition of secretory 
granules with plasma membranes in neurons involves 
a complex set of interactions between proteins ex- 
pressed in plasma membrane (e.g. syntaxin, SNAP- 
25, and synapotagmin) and in secretory granule 
membranes (e.g. synaptobrevin) [39]. These proteins 
are also expressed in pancreatic islets [24], suggesting 
that there are common features between synaptic 
vesicle exocytosis and insulin secretion. Our findings 
indicate that a brain cytosolic protein that is neutral- 
ized by an anti-GAPDH antibody can catalyze fu- 
sion of isolated secretory granule membranes with 
plasma membranes prepared from pancreatic islets. 
Our findings also demonstrate he presence of a sim- 
ilar fusion-catalyzing activity in the cytosol of HIT 
insulinoma cells. 
These findings are of great interest with respect to 
the regulation of insulin secretion. The potential in- 
volvement of a GAPDH isoform in catalyzing fusion 
of islet secretory granules and plasma membranes i  
particularly intriguing because all known carbohy- 
drate fuel insulin secretagogues yield glyceralde- 
hyde-3-phosphate as an intermediate [2,45]. Carbo- 
hydrate fuels which enter glycolysis distal to 
glyceraldehyde-3-phosphate (e.g. lactate and pyru- 
vate) are readily metabolized to CO2, but fail to in- 
duce insulin secretion [2,45]. Glyceraldehyde is a 
more potent insulin secretagogue on a molar basis 
than is glucose [2,46] and its potency as an insulin 
secretagogue exceeds its suitability as a fuel [2]. The 
discrepancy between the fuel and secretagogue prop- 
erties of glucose and glyceraldehyde in comparison 
with pyruvate and lactate, has long been interpreted 
to indicate that a signal triggering insulin secretion is
generated in the glycolytic pathway between glycer- 
aldehyde-3-phosphate nd pyruvate [2,45]. The na- 
ture of this signal has not yet been established. The 
present results suggest the possibility that this signal 
might involve activation of a fusion-catalyzing 
GAPDH isoform in [3-cells by glyceraldehyde-3- 
phosphate itself or by downstream etabolic prod- 
ucts known to interact with other isoforms of 
GAPDH. Such activation might be imagined to in- 
volve dissociation of the fusion-catalyzing GAPDH 
isoform from an endogenous inhibitor which sup- 
presses the latent fusion-catalyzing activity in cytosol 
from brain and HIT insulinoma cells. 
Although the function of GAPDH in glycolysis is 
well-recognized, a variety of non-glycolytic activities 
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have been attributed to GAPDH, including nucleic 
acid binding and DNA repair and interactions with 
membranes and the cytoskeleton [47-57]. These ob- 
servations suggest that isoforms of GAPDH may 
play multifunctional roles in cell biology, and the 
association of such isoforms with cell membranes 
[48,51,52] and with microtubular structures [49] is 
compatible with the possibility that one such func- 
tion could be to facilitate fusion of microtubule-as- 
sociated insulin secretory granules [44] with plasma 
membranes in glucose-stimulated islets. It is of inter- 
est, in this regard, that adaptation of native islet [3- 
cells to chronic hyperglycemia is characterized by 
enhanced insulin secretory function [58,59]. Simi- 
larly, prolonged exposure of the clonal pancreatic 
[~-cell ine INS-1 to high concentrations of glucose 
results in augmentation of insulin secretion by a 
mechanism that requires gene transcription and 
mRNA translation [60]. In INS-1 cells, the enhanced 
insulin secretory function induced by prolonged ex- 
posure to glucose is associated with increases in the 
levels of GAPDH mRNA and protein that are sim- 
ilar in magnitude to the increase in secretory rate 
[60]. Although this could reflect a role for metabolic 
signals derived from the glycolytic activity of 
GAPDH in insulin secretion [61-63], it is also possi- 
ble that up regulation of fusogenic isoforms GAPDH 
is required to support the greater ate of fusion be- 
tween secretory granules and plasma membranes that 
occurs in the hypersecretory state. 
Of equal interest is the possibility that modifica- 
tion of fusogenic GAPDH isoforms might be in- 
volved in the profound reduction in glucose-induced 
insulin secretion that occurs when islets are incu- 
bated with the cytokine interleukin-1 (IL-1). This 
IL-l-induced suppression of insulin secretion in- 
volves induction of the inducible isoform of nitric 
oxide synthase and overproduction of nitric oxide 
and is preventable by nitric oxide synthase inhibitors 
[64-73]. It is not yet known precisely how nitric ox- 
ide impairs glucose-induced insulin secretion, but NO 
is known to induce post-translational modifications 
of GAPDH which reduce its catalytic activity [74,75]. 
These modifications include S-nitrosylation at thiol 
groups and subsequent covalent attachment of 
NADH [74,75]. It is possible that such modifications 
of fusogenic isoforms of GAPDH by NO could re- 
duce their ability to catalyze membrane fusion and 
that this phenomenon could contribute to the IL-1- 
induced suppression of insulin secretion. 
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